Statin Pharmacogenomics: A multi-gene PK-PD modeling approach

他汀类药物基因组学：多基因 PK-PD 建模方法

基本信息

批准号：
8331521
负责人：
Joseph Paul Kitzmiller
金额：
$ 19.11万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-15 至 2016-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8331521
关键词：
Academic Medical Centers Accounting Address Adverse effects Adverse event Alleles Atherosclerosis Award Biological Markers Biometry C-reactive protein CETP gene CYP3A4 gene Cardiovascular Diseases Cardiovascular system Cause of Death Cells Cessation of life Clinical Clinical Pharmacology Clinical Sciences Clinical Trials Design Doctor of Philosophy Dose Enzyme Interaction Enzymes Epidemic Epidemiology Ethics Event Frequencies Funding Genes Genetic Genetic Polymorphism Goals Health Hepatic Hepatocyte High Density Lipoproteins Hydroxymethylglutaryl-CoA reductase Incidence Individual Internal Medicine Introns Lipids Liver Function Tests Lovastatin Low-Density Lipoproteins Measures Medicine Mentors Methodology Mission Modeling Morbidity - disease rate Muscle Myocardial Infarction Myopathy Ohio Outcome Outcomes Research Patient Selection Patients Penetrance Pharmaceutical Preparations Pharmacogenomics Pharmacotherapy Physicians Plasma Reporting Research Research Activity Research Personnel Sample Size Serum Simvastatin Stroke Techniques Testing Therapeutic Thick Toxic effect Training Support Translational Research United States United States National Institutes of Health Variant atorvastatin cardiovascular risk factor career development clinically significant cost cost effectiveness experience gene interaction gene therapy improved inhibitor/antagonist intima media mortality novel patient oriented research prevent research and development response

项目摘要

DESCRIPTION (provided by applicant): The candidate, Joseph P. Kitzmiller MD, PhD is a Clinical Pharmacology Physician at the Ohio State University Medical Center. Through this award he seeks to become an independent investigator in patient-oriented research, with a focus on pharmacogenomics as applied to personalized medicine. Specifically, he will focus on developing a comprehensive and adaptable multi-gene model for predicting how individual patients respond to statin therapy. Dr. Kitzmiller will be mentored by Dr. Wolfgang Sadee, a renowned expert in pharmacogenomics, and Dr. Rebecca Jackson, and internal medicine clinician and experienced translational researcher. Together with his mentors, both strongly connected with the NIH Pharmacogenomics Research Network (PGRN) and the NIH Clinical and Translational Science Consortium (CSTC), Dr. Kitzmiller will investigatey the influence of various genetic factors on patient's response to statin medications. Importantly, atherosclerotic cardiovascular disease is a growing epidemic, associated with unacceptable mortality, morbidity, and cost. Dr. Kitzmiller's primary goal is to develop pharmacogenomic patient-selection strategies for improving statin efficacy and cost-effectiveness and for reducing the incidence of associated adverse effects. Dr. Kitzmiller will supplement his research activities with didactics in clinical trial design and conduct, epidemiology and outcomes research, biostatistics, and ethics. In addition, he will gain ground-breaking experience in both pharmacogenomics and pharmacoanalytic techniques.

描述（由申请人提供）：候选人 Joseph P. Kitzmiller MD、PhD 是俄亥俄州立大学医学中心的临床药理学医师。通过该奖项，他寻求成为一名以患者为导向的研究的独立研究者，重点关注应用于个性化医疗的药物基因组学。具体来说，他将专注于开发一种全面且适应性强的多基因模型，用于预测个体患者对他汀类药物治疗的反应。 Kitzmiller 博士将得到药物基因组学著名专家 Wolfgang Sadee 博士以及内科临床医生和经验丰富的转化研究员 Rebecca Jackson 博士的指导。 Kitzmiller 博士将与他的导师（均与 NIH 药物基因组学研究网络 (PGRN) 和 NIH 临床与转化科学联盟 (CSTC) 密切联系）一起，研究各种遗传因素对患者对他汀类药物反应的影响。重要的是，动脉粥样硬化性心血管疾病是一种日益流行的疾病，其死亡率、发病率和费用令人无法接受。 Kitzmiller 博士的主要目标是开发药物基因组患者选择策略，以提高他汀类药物的疗效和成本效益，并减少相关不良反应的发生率。 Kitzmiller 博士将通过临床试验设计和实施、流行病学和结果研究、生物统计学和伦理学方面的教学来补充他的研究活动。此外，他还将在药物基因组学和药物分析技术方面获得突破性的经验。